Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Myriad Genetics, a healthcare company, has acquired the exclusive North American license to specific application of novel proprietary technology used to perform pharmacokinetic analysis of therapeutic drugs in patients, from Saladax Biomedical, a developer of personalized chemotherapy management immunoassays.
Subscribe to our email newsletter
The technology allows a physician to adjust a patient’s dose of chemotherapy to provide optimal patient exposure to the chemotherapy to help improve efficacy and minimize toxicity during the course of treatment.
Gregory Critchfield, president of Myriad Genetic Laboratories, said: “We are very pleased to be working with Saladax in the commercialization of this exciting technology. This effort will not only benefit patients, but will complement our current product portfolio and will be readily sold through our existing 150-person oncology salesforce.”